Solid Cancer Clinical Trial
Official title:
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-directed Antibody-drug Conjugate, in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer
This study will focus on R-DXd in participants with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer. R-DXd is an antibody-drug conjugate that specifically binds to CDH6, which is overexpressed in tumor cells. The Phase 2 dose-optimization part of the study (Part A) intends to define the recommended dose based on safety and efficacy, while the Phase 3 (Part B) part of the study will compare R-DXd with Investigator's choice of chemotherapy and further evaluate efficacy. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03721679 -
Poly-ICLC (Hiltonol) and Anti-PD1 or Anti-PD-L1
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02884375 -
Elderly CAncer Patient
|
N/A | |
| Completed |
NCT00925743 -
A Study to Evaluate the Effects of Combining Cabazitaxel With Cisplatin Given Every 3 Weeks in Patients With Advanced Solid Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT02376127 -
Metastatic Spinal Bone Marrow Response to Radiation Therapy Using T1 Weighted Dynamic Contrast-Enhanced Perfusion
|
||
| Completed |
NCT02959905 -
Treatment of Advanced Solid Tumors With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)
|
Phase 1 | |
| Recruiting |
NCT04248348 -
Metaxa Hospital THromboprophylaxis Program in Oncological & Surgical Patients
|
||
| Recruiting |
NCT03311100 -
Immunological Profile of Solid Tumors Sample
|
N/A | |
| Completed |
NCT03890731 -
A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed
|
Phase 2 |